Your browser doesn't support javascript.
loading
Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome.
Guijarro, Francesca; López-Guerra, Monica; Morata, Jordi; Bataller, Alex; Paz, Sara; Cornet-Masana, Josep Maria; Banús-Mulet, Antònia; Cuesta-Casanovas, Laia; Carbó, Josep Maria; Castaño-Díez, Sandra; Jiménez-Vicente, Carlos; Cortés-Bullich, Albert; Triguero, Ana; Martínez-Roca, Alexandra; Esteban, Daniel; Gómez-Hernando, Marta; Álamo Moreno, José Ramón; López-Oreja, Irene; Garrote, Marta; Risueño, Ruth M; Tonda, Raúl; Gut, Ivo; Colomer, Dolors; Díaz-Beya, Marina; Esteve, Jordi.
Afiliación
  • Guijarro F; Pathology Department, Hematopathology Section, Hospital Clínic Barcelona, Barcelona, Spain.
  • López-Guerra M; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Morata J; Pathology Department, Hematopathology Section, Hospital Clínic Barcelona, Barcelona, Spain.
  • Bataller A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Paz S; Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain.
  • Cornet-Masana JM; Centro Nacional de Análisis Genómico, Barcelona, Spain.
  • Banús-Mulet A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Cuesta-Casanovas L; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Carbó JM; Pathology Department, Hematopathology Section, Hospital Clínic Barcelona, Barcelona, Spain.
  • Castaño-Díez S; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Jiménez-Vicente C; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Cortés-Bullich A; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Triguero A; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.
  • Martínez-Roca A; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Esteban D; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Gómez-Hernando M; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Álamo Moreno JR; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • López-Oreja I; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Garrote M; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Risueño RM; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Tonda R; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Gut I; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Colomer D; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
  • Díaz-Beya M; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Esteve J; Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain.
Blood Adv ; 7(19): 5799-5811, 2023 10 10.
Article en En | MEDLINE | ID: mdl-37450374
ABSTRACT
Germ line predisposition in acute myeloid leukemia (AML) has gained attention in recent years because of a nonnegligible frequency and an impact on management of patients and their relatives. Risk alleles for AML development may be present in patients without a clinical suspicion of hereditary hematologic malignancy syndrome. In this study we investigated the presence of germ line variants (GVs) in 288 genes related to cancer predisposition in 47 patients with available paired, tumor-normal material, namely bone marrow stroma cells (n = 29), postremission bone marrow (n = 17), and saliva (n = 1). These patients correspond to 2 broad AML categories with heterogeneous genetic background (AML myelodysplasia related and AML defined by differentiation) and none of them had phenotypic abnormalities, previous history of cytopenia, or strong cancer aggregation. We found 11 pathogenic or likely pathogenic variants, 6 affecting genes related to autosomal dominant cancer predisposition syndromes (ATM, DDX41, and CHEK2) and 5 related to autosomal recessive bone marrow failure syndromes (FANCA, FANCM, SBDS, DNAJC21, and CSF3R). We did not find differences in clinical characteristics nor outcome between carriers of GVs vs noncarriers. Further studies in unselected AML cohorts are needed to determine GV incidence and penetrance and, in particular, to clarify the role of ATM nonsense mutations in AML predisposition.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Neoplasias Hematológicas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda / Neoplasias Hematológicas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: España